SDC1 and Miyoshi myopathy: In addition, ZnPPIX increased apoptosis of CD138+ cells from stage I, stage II and stage III MM patients by 18.56%, 22.57% and 16.34%, respectively, compared with those without ZnPPIX treatment (Figure 2J).